So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...
On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair ... with the scientific team ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Management also lowered the midpoint ... The Motley Fool Stock Advisor analyst team just identified what they believe are the ...
Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...
Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ETCompany ParticipantsDavid Constable - Chairman & CEOJoe ...
Even a juggernaut like Eli Lilly (NYSE: LLY) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat, ...
INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker ...
NEW YORK (AP) — U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies ... chief economist at Annex Wealth Management. A separate report on Wednesday suggested ...
With the rise of exchange-traded funds, or ETFs, that let you buy and sell throughout the trading day, mutual funds have fallen out of the limelight. But don't write off the old stalwart of ...